Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Conditions:   Nasopharyngeal Nonkeratinizing Carcinoma;   Recurrent Nasopharyngeal Undifferentiated Carcinoma;   Stage III Nasopharyngeal Undifferentiated Carcinoma;   Stage IV Nasopharyngeal Undifferentiated CarcinomaInterventions:   Biological: Nivolumab;   Other: Laboratory Biomarker AnalysisSponsor:   National Cancer Institute (NCI)Not yet recruiting - verified January 2015

Source: ClinicalTrials.gov - January 12, 2015 Category: Research Source Type: clinical trials